Medically reviewed by Forest Miller, OTR/L When you are managing metastatic breast cancer, planning for the future is both ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...

Salk scientists have found that eliminating the bile acid-producing protein BAAT and supplementing with the bile acid UDCA ...

The life expectancy with Zollinger-Ellison syndrome can depend on whether tumors have metastasized, or spread, to the liver.

Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the ...

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...